Director Michael B. Hoffman filed a Form 4 with the SEC on November 6, 2026, disclosing the acquisition of 5,000,000 shares of Annovis Bio, Inc. common stock and 5,000,000 warrants on that same date.
Key Highlights
- Transaction: Michael B. Hoffman, a director of Annovis Bio, Inc. (NASDAQ:ANVS), acquired 5,000,000 shares of common stock on November 6, 2026, with transaction code "P" (purchase).
- Combined price: According to the filing, the 5,000,000 shares and 5,000,000 warrants were "acquired for a combined price of $1.00 per share."
- Warrants acquired: Hoffman also acquired 5,000,000 warrants, exercisable from November 6, 2026, through November 6, 2031, at an exercise price of $1.00, at a price of $0 per warrant.
- Direct holdings after transaction: Following the reported transaction, Hoffman directly and beneficially owns 8,364,883 shares of common stock.
- Indirect holdings: An additional 223,357 shares are held indirectly through The 2024 Hoffman Family Trust, over which the reporting person holds voting and investment power.
- Signing authority: The form was signed by Maria Maccecchini as Attorney-in-Fact on November 6, 2026.
Hoffman's November 6 Purchase of Annovis Bio Common Stock and Warrants
According to the Form 4 filed with the SEC, Michael B. Hoffman, identified as a director of Annovis Bio, Inc. (NASDAQ:ANVS), purchased 5,000,000 shares of Annovis Bio common stock on November 6, 2026. The filing states that the 5,000,000 shares of common stock and 5,000,000 warrants described in Tables I and II, respectively, "were acquired for a combined price of $1.00 per share." The transaction is coded "P," indicating a purchase in the open market or directly from the issuer.
In addition to the common shares, the filing discloses that Hoffman acquired 5,000,000 warrants, each representing the right to acquire one share of common stock. The warrants carry an exercise price of $1.00 and were acquired at a price of $0. They became exercisable on November 6, 2026, and expire on November 6, 2031, according to the filing.
Following these transactions, the filing reports that Hoffman directly and beneficially owns 8,364,883 shares of common stock. An additional 223,357 shares are held indirectly through The 2024 Hoffman Family Trust, a family trust formed by the reporting person. The filing notes that Hoffman holds "voting and investment power over such shares." The form was executed by Maria Maccecchini as Attorney-in-Fact and dated November 6, 2026.
What Was Disclosed
Director Michael B. Hoffman reported a purchase of 5,000,000 shares of Annovis Bio common stock and 5,000,000 warrants on November 6, 2026, at a combined price of $1.00 per share, bringing his direct beneficial ownership to 8,364,883 shares.





Please wait processing your request...